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Abstract
Alzheimer’s disease (AD) is a severe1 age-related neurodegenerative disorder characterized by 
accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles, synaptic and neuronal loss, 
and cognitive decline. Several genes have been implicated in AD, but chromatin state alterations 
during neurodegeneration remain uncharacterized. Here, we profile transcriptional and chromatin 
state dynamics across early and late pathology in the hippocampus of an inducible mouse model of 
AD-like neurodegeneration. We find a coordinated downregulation of synaptic plasticity genes 
and regulatory regions, and upregulation of immune response genes and regulatory regions, which 
are targeted by factors that belong to the ETS family of transcriptional regulators, including PU.1. 
Human regions orthologous to increasing-level enhancers show immune cell-specific enhancer 
signatures as well as immune cell expression quantitative trait loci (eQTL), while decreasing-level 
enhancer orthologs show fetal-brain-specific enhancer activity. Notably, AD-associated genetic 
variants are specifically enriched in increasing-level enhancer orthologs implicating immune 
processes in AD predisposition. Indeed, increasing enhancers overlap known AD loci lacking 
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protein-altering variants and implicate additional loci that do not reach genome-wide significance. 
Our results reveal new insights into the mechanisms of neurodegeneration and establish the mouse 
as a useful model for functional studies of AD regulatory regions.
Gene expression2,3 and genetic variation4 studies suggest gene-regulatory changes may 
underlie AD, but regulatory epigenetic alterations during neurodegeneration remain 
uncharacterized, given the inaccessible nature of human brain samples. To address this need, 
we profiled transcriptional and epigenomic changes during neurodegeneration in the 
hippocampus of the CK-p25 mouse model of AD5–7 and CK littermate controls at both early 
and late stages of neurodegeneration (2 weeks and 6 weeks after p25 induction). CK-p25 
mice, in which accumulation of the Cdk5 activator p25 is inducible, exhibit DNA damage, 
aberrant gene expression and elevated amyloid-β levels at early stages7, followed by 
neuronal and synaptic loss and cognitive impairment at late stages5,6.
For transcriptome analysis, we used RNA sequencing to quantify gene expression changes 
for 13,836 ENSEMBL genes (see Methods; Extended Data Fig. 1a; Supplementary Table 1). 
We found 2,815 upregulated genes and 2,310 downregulated genes in the CK-p25 AD 
mouse model as compared to CK littermate controls (at q < 0.01; Supplementary Table 1), 
which we classified into transient (2 weeks only), late-onset (6 weeks only), and consistent 
(both) expression classes (Fig. 1a; Extended Data Fig. 4a, Supplementary Table 1). These 
showed distinct functional enrichments (Fig. 1a; Supplementary Table 2), with transient-
increase genes enriched in cell cycle functions (P < 10−92), consistent-increase genes 
enriched in immune (P < 10−10) and stimulus response functions (P < 10−4), and consistent- 
and late-decrease genes enriched in synaptic and learning functions (P < 10−12).
These coordinated neuronal and immune changes are consistent with the pathophysiology of 
AD2 and probably reflect both cell-type-specific expression changes as well as changes in 
cell composition. Indeed, comparison with expression in microglia8 (the resident immune 
cells of the brain) shows that both, cell type composition (P = 2.7 × 10−4) and microglia-
specific activation (P = 2.9 × 10−6) significantly contribute to the gene expression changes 
(see Methods). Additionally, reverse transcription followed by quantitative PCR (RT-qPCR) 
of increased-level genes in purified CD11b+ CD45low microglia populations confirms cell-
type-specific activation for five of the seven microglia-specific genes tested (Extended Data 
Fig. 2).
Confirming the biological relevance of our mouse model for human AD, the observed 
changes in gene expression in mouse, especially for the consistent and late classes, agreed 
with gene expression differences between 22 AD patients and 9 controls in human post-
mortem laser capture microdissected hippocampal gray matter2 (Fig. 1b). The enriched Gene 
Ontology classes also agreed between mouse and human, with higher immune gene 
expression and lower neuronal gene expression in AD patients (Fig. 1c).
For epigenome analysis, we used chromatin immunoprecipitation sequencing (ChIP-seq) to 
profile seven chromatin marks9: H3K4me3 (associated primarily with active promoters); 
H3K4me1 (enhancers); H3K27ac (enhancer/promoter activation); H3K27me3 (Polycomb 
repression); H3K36me3 and H4K20me1 (transcription); and H3K9me3 (heterochromatin) 
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(Extended Data Fig. 1a). We used ChromHMM (http://compbio.mit.edu/ChromHMM/) to 
learn a chromatin state model (see Methods, Extended Data Fig. 3a) defined by recurrent 
combinations of histone modifications, consisting of promoters, enhancers, transcribed, 
bivalent, repressed, heterochromatin and low-signal states (Extended Data Fig. 3a). We 
defined 57,840 active promoters using H3K4me3 peaks within promoter chromatin states, 
and 151,447 active enhancer regions using H3K27ac peaks within enhancer chromatin states 
(Extended Fig. 1a; Supplementary Table 3; see Methods).
We mapped orthologous genes between mouse and human using ENSEMBL one-to-one 
orthologs (see Methods). We also mapped orthologous noncoding regions using multiple 
mammalian sequence alignments, mapping each mouse peak to its best human match (see 
Methods). We found matches for 90% of promoter regions, 84% of enhancers, 74% of 
Polycomb-repressed regions, and 33% of heterochromatin regions (Supplementary Table 3). 
Comparing our mouse chromatin states to human hippocampus chromatin states10, we found 
significant epigenomic conservation at orthologous noncoding regions (Extended Data Fig. 
3b), consistent with recent results11.
We quantified epigenomic changes in promoter regions using relative differences in 
H3K4me3 levels resulting in 3,667 increased-level and 5,056 decreased-level peaks (q < 
0.01, Extended Data Fig. 4b and Supplementary Table 3), which we classified into transient, 
consistent, and late-stage, as for gene expression changes. For enhancer regions, we used 
relative levels of H3K27ac, resulting in 2,456 increased-level and 2,154 decreased-level 
peaks (Extended Data Fig. 4c; Supplementary Table 3). Only a very small number of peaks 
showed differences in Polycomb-repressed and heterochromatin regions, leading us to focus 
on enhancer and promoter changes for the remaining analyses (Extended Data Fig. 4d, e; 
Supplementary Table 3).
Genes flanking increased- and decreased-level regulatory regions (see Methods) showed 
consistent gene expression changes for both promoter and enhancers regions (Extended Data 
Fig. 5), and were consistently enriched in immune and stimulus-response functions for 
increased-level enhancers and promoters, and in synapse and learning-associated functions 
for deceased-level enhancers and promoters (Fig. 1d, e), consistent with our Gene Ontology 
results of changing gene expression levels.
Increased- and decreased-level regulatory regions showed distinct regulatory motif 
enrichments (Fig. 1f, g). Increased-level peaks were enriched in NFκB, E2F, PPARG, IRF 
and PU.1 (ref. 12) transcription factor motifs for both enhancers and promoters, consistent 
with immune regulator targeting. Decreased-level peaks in enhancers were enriched for 
DNA-binding RFX motifs, and peaks in promoters were enriched for zinc-finger ZIC 
motifs, two known neurodevelopmental regulators13,14.
Consistent with the observed motif enrichments, increased-level enhancers and promoters 
showed in vivo binding of PU.1 in mouse embryos15,16 (Fig. 1h, i). Only increased-level 
promoters were bound in macrophages and BV-2 microglial-like cells17–19 that are both 
implicated in AD20, while both increased- and decreased-level promoters were bound in 
several immune cell lineages (Fig. 1h). The PU.1 regulator itself (encoded by the SPI1 
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gene), showed increased expression and enhancer levels (Extended Data Fig. 1b), possibly 
contributing to immune enhancer and promoter upregulation, consistent with roles for PU.1, 
ETS-1, and other ETS family members in microglia activation and proliferation during 
neurodegeneration21,22. By contrast, neuronal function regulators were not enriched in 
increased-level enhancers (except for a weak enrichment of fetal brain CREB, Fig. 1i), 
consistent with primarily immune and inflammatory function of these regions.
Decreased-level enhancers and promoters were targeted by different regulators, suggesting 
distinct regulatory programs. Decreased-level promoters were preferentially bound by 
CREB and SRF (P < 10−21 and P < 10−16), two known regulators of neuronal activity in 
cortical neurons23, and decreased-level enhancers were preferentially bound by CBP 
(Phypergeometric = 5.4 × 10−20), a known co-activator for neuronal activity16 (Fig. 1h, i). 
Surprisingly, p300-bound regions15 did not show any enrichment, suggesting distinct roles 
for CBP and p300, despite a general association with enhancers for both. The distinct 
neuronal and immune targeting of decreased-level and increased-level regulatory regions 
provides a mechanistic basis for the expression differences observed for neuronal and 
immune genes, and suggests potential therapeutic targets for reversing observed alterations 
during neurodegeneration.
On the basis of chromatin state annotations in 127 human cell types and tissues10 (Fig. 3a 
and Supplementary Table 4) regions orthologous to increased-level enhancers in mouse 
showed immune cell enhancer activity in human (P < 10−100), while orthologs of decreased-
level enhancers in mouse showed fetal brain tissue enhancer activity in human (P < 10−8 
consistent; P < 10−17 late-stage; Fig. 2a; Supplementary Table 4). Adult brain tissues 
(including hippocampus) were not as strongly enriched, suggesting changes are biased 
towards neuronal plasticity. These results are consistent with decreased neuronal plasticity, 
and increased microglial activation and proliferation during AD progression24.
To verify whether the increased-level putative enhancer regions were indeed functional, we 
used a luciferase reporter assay to evaluate their ability to drive in vitro gene expression in 
immortalized murine microglial (BV-2) and neuroblastoma (N2a) cell lines. Eight of the 
nine increased-level human orthologs tested were indeed able to drive in vitro reporter 
expression. Two of these, BIN1 and ZNF710, were active in both cell types, while the 
remaining six showed a BV-2 cell-specific increase in luciferase expression (Fig. 2b and 
Supplementary Table 5) confirming both, functional conservation and tissue specificity of 
increased-level enhancer regions implicated by our mouse model of AD.
Human orthologs of increased-level enhancers were also enriched for expression 
quantitative trait loci (eQTLs) in CD4+ T-cells and CD14+ monocytes25,26 (Extended Data 
Fig. 6, Supplementary Table 6), indicating they harbor driver mutations controlling immune 
cell regulatory programs. The enrichment was strongest for CD14+ monocytes (Extended 
Data Fig. 6), which also showed the highest enhancer enrichment and is consistent with the 
observed inflammatory response Gene Ontology category.
To test whether the implicated regulatory regions are causal, we examined their enrichment 
for AD-associated variants from genome-wide association studies (GWAS). Genetic 
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variants associated with AD in a meta-analysis of ~74,000 individuals4, were enriched in 
increased-level enhancer orthologs (Fig. 2c), (4.4-fold enrichment, binomial P = 1.2 × 10−10 
at GWAS cutoff P < 0.001; 9.7-fold enrichment, binomial P < 3.7 × 10−6 at GWAS cutoff P 
< 10−5). By contrast, decreased-level enhancer orthologs were surprisingly not enriched 
(0.61-fold), suggesting a causal role specifically for immune-related processes. Promoter 
regions were only weakly enriched, strongly implicating distal enhancers in mediating AD 
predisposition (Extended Data Fig. 7).
Across diverse cell types and tissues, we found concordance between the enrichment for AD 
GWAS single nucleotide polymorphisms (SNPs) and the enrichment for increased-level 
enhancer orthologs (R2 = 0.49; Fig. 2d, Extended Data Fig. 8a, left and Supplementary 
Table 4), with CD14+ immune cells being the most enriched in both, followed by other 
immune cell types, and with fetal brain enhancers showing the smallest enrichment in both. 
By contrast, decreasing enhancers orthologs showed a very weak correlation (R2 < 0.08) 
(Fig. 2e, Extended Data Fig. 8b, right and Supplementary Table 4). The increased-level 
enhancer ortholog enrichment for AD GWAS SNPs persisted both within CD14+ enhancers 
(3.0-fold enrichment, binomial P = 1.3 × 10−5) and outside CD14+ enhancers (3.4-fold, P = 
0.005) suggesting it is not solely a feature of CD14+ cell type enrichment (see Methods).
These results are consistent with enhanced microglial expression of CD14 in brains of 
animal models of AD, and a regulatory role of the CD14 receptor in microglial 
inflammatory response, which modulates amyloid-β deposition24. Thus, the enrichment of 
AD-associated variants in CD14+ primary immune cells, but not neuronal cells, indicates 
that AD genetic predisposition is primarily associated with immune function, while decrease 
in neuronal plasticity may be affected primarily by non-genetic effects, such as diet, 
education, physical activity and age, which are thought to lead to epigenetic changes related 
to cognitive reserve27.
We next utilized the epigenomic annotations of increased-level enhancer orthologs to gain 
insights into AD-associated loci (Supplementary Table 7). Among the 20 genome-wide 
significant AD-associated loci4, 11 contain no protein-altering SNPs in linkage 
disequilibrium (LD), indicating they may have noncoding roles. Of these, 5 localize within 
increased-level enhancer orthologs, including two well-established GWAS loci (PICALM, 
BIN1), and three loci (INPP5D, CELF1 (also containing the SPI1 gene), PTK2B) only 
recently recognized as significant by combining all AD cohorts.
For INPP5D (Fig. 3a), a known regulator of inflammation28, the most significant variants 
localize within an increased-level enhancer ortholog, which also shows CD14+ enhancer 
activity. In the CELF1 locus (Fig. 3b) a large region of association spans several genes, but 
the strongest genetic signal (P = 2 × 10−6) localizes upstream of SPI1 (PU.1), and 
specifically within an increased-level enhancer ortholog that is also active in immune cells. 
We confirmed that the AD-associated C-T substitution, rs1377416, in the SPI1 enhancer 
leads to increased in vitro enhancer activity in murine BV-2 microglia cells using a 
luciferase reporter assay (Fig. 3d). In addition, the AD-associated SNP rs55876153 near 
SPI1, which overlaps an increased-level mouse enhancer ortholog, is in strong linkage 
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disequilibrium (LD = 0.89, see Methods) with a known SPI1 eQTL, rs10838698 (ref. 25), 
even though it did not significantly alter enhancer activity in the luciferase assay.
Outside known GWAS loci, an additional 22 weakly-associated regions (3.9-fold, P < 4.9 × 
10−7) contain variants within increased-level enhancer orthologs (Supplementary Table 7), 
of which 17 lack protein-altering variants in LD (R2 < 0.4), providing strong candidates for 
directed experiments. One such example includes ABCA1 (P = 6.9 × 10−5, Fig. 3c), a 
paralog of AD-associated ABCA7 and encoding a glial-expressed transporter that influences 
APOE metabolism in the central nervous system29. The region lacks protein-altering 
variants and all five SNPs in the cluster of association lie specifically within an increased-
enhancer ortholog, which is also active in CD14+ immune cells and, to a lesser extent, in 
human hippocampus and fetal brain.
Overall, our study revealed contrasting changes in immune and neuronal genes and 
regulatory regions during AD-like neurodegeneration in mouse, strong human-mouse 
conservation of gene expression and epigenomic signatures, and enrichment of AD-
associated loci in increased-level enhancer orthologs in human. While immune genes are 
known to be among the most significant genetic loci associated with AD, the depletion of 
neuronal promoters and enhancers is particularly striking for a cognitive disorder with well-
established environmental and experiential factors that include diet, exercise, education and 
age. These results are consistent with a model in which increased immune susceptibility to 
environmental factors during aging and cognitive decline is mediated by interactions 
between genetically driven immune cell dysregulation and environmentally driven 
epigenomic alteration in neuronal cells.
Our study also illustrates the power of model organisms for the study of human disease 
progression, especially for disorders affecting inaccessible tissues for which only post-
mortem samples are available in human. We find that molecular changes in both genes and 
regulatory regions are highly conserved between human AD and CK-p25 
neurodegeneration, enabling detailed studies of the molecular signatures associated with 
disease progression across diverse environmental conditions, in a variety of brain regions 
and cell types, and in response to therapeutic agents before or after disease onset.
Lastly, our results suggest specific therapeutic targets for AD, including putative causal 
nucleotides lying in increased-level enhancer orthologs that may be targeted by CRISPR/
Cas9 genome editing30, and trans-acting regulators. In particular, the transcription factor 
PU.1 is implicated as a therapeutic target by its genetic association with AD, as well as the 
enrichment of the PU.1 motif and the PU.1 in vivo binding sites at increased-level regulatory 
regions during mouse neurodegeneration. The conservation of neuronal and immune 
regulatory circuitry between mouse and human suggests that CK-p25 mice may offer a 
powerful model for studying the gene-regulatory and cognitive effects of such interventions.
Gjoneska et al. Page 6
Nature. Author manuscript; available in PMC 2015 August 19.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Materials and Methods
Animals
All mouse work was approved by the Committee on Animal Care of the Division of 
Comparative Medicine at MIT. Adult (3-months-old) female double-transgenic CK-p25 (ref. 
5) mice and their respective control littermates were used for the experiments. Brain tissue 
was collected at either 2 or 6 weeks following p25 induction. Upon dissection tissue was 
flash-frozen in liquid nitrogen. No animals were excluded from the study and no 
randomization or blinding was required.
Chromatin Immunoprecipitation (ChIP)
Mouse hippocampus was harvested immediately after euthanasia. Chromatin 
immunoprecipitation was then performed as described in Broad ChIP protocol (http://
www.roadmapepigenomics.org/protocols/type/experimental/). Briefly, tissues were minced 
and crosslinked in 1% formaldehyde (Thermo Scientific) for 15 min at room temperature 
and quenched with glycine for 5 min (Sigma). The samples were homogenized in cell lysis 
buffer containing proteinase inhibitors (complete, Roche) and chromatin was then 
fragmented to a size range of ~200–500 bp using a Branson 250 digital sonifier. Solubilized 
chromatin was then diluted and incubated with ~1 μg antibody at 4°C overnight. Immune 
complexes were captured with Protein A-sepharose beads, washed and eluted. Enriched 
chromatin was then subjected to crosslink reversal and proteinase K digestion at 65°C, 
phenol-chloroform extraction and ethanol precipitation. Isolated ChIP DNA was 
resuspended and quantified using the Qubit assay (Invitrogen). H3K4me1 (Abcam, ab8895), 
H3K4me3 (Millipore, #07-473), H3K9me3 (Abcam, ab8898), H3K27me3 (Millipore, 
#07-449), H3K27ac (Abcam, ab4729), H3K36me3 (Abcam, ab9050) and H4K20me1 
(Abcam, ab9051) were used to immunoprecipitate endogenous proteins.
ChIP-seq high-throughput sequencing, read mapping and quality control
Sequencing libraries were prepared from ~1–5 ng ChIP (or input) DNA as described 
previously31. Gel electrophoresis was used to retain library fragments between 300 and 600 
bp. Prior to sequencing, libraries were quantified using Qubit (Invitrogen) and quality-
controlled using Agilent’s Bioanalyzer. 36 bp single end sequencing was performed using 
the Illumina HiSeq 2000 platform according to standard operating procedures. For each 
histone modification, five biological replicate datasets were produced with corresponding 
whole cell extract controls, except for H3K4me3, H4K20me1and H3K27me3 in the 2 wk 
control (CK) sample where optimal amount of reads for sufficient coverage was obtained 
from four biological replicates. Reads were mapped to the mm9 reference mouse genome 
using MAQ v0.7.1-9 using default parameters32. Reads mapping to multiple locations were 
discarded. Duplicates were marked and filtered using PICARD (http://
picard.sourceforge.net/). After filtering, roughly 55–60 million unique reads were obtained 
for each histone modification in each condition (~9–12 million reads per replicate) and 
~110–145 million reads in total for the whole-cell extract controls in each condition. All 
replicate datasets passed quality control based on ENCODE ChIP-seq data standards based 
on read quality, read mapping statistics, library complexity and strand cross-correlation 
analysis (to measure signal-to-noise ratios)33.
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RNA sequencing
Mouse brains were homogenized and total RNA was extracted using Trizol reagent 
(Ambion). Total RNA was quality-controlled using Agilent’s Bioanalyzer and prepared for 
sequencing using Illumina’s TruSeq Stranded Total RNA Sample Preparation Kit with Ribo-
Zero. High-throughput sequencing was performed on an Illumina HiSeq 2000 platform. 
Roughly 15 million 76 pair-end reads were generated for each dataset. Sequence reads were 
aligned to mouse mm9 genome with Bowtie. Based on the reproducibility of the results (Fig. 
2a), three replicate biological datasets were produced for each condition. A small number of 
replicates suffice for RNA-seq studies34 and we were able to detect large-scale changes in 
read counts in coherent Gene Ontology categories, with similarities to human AD (Fig. 2c, 
d). Therefore, we decided that additional replicates were not necessary.
Peak calling and signal coverage tracks for ChIP-seq data
For each histone modification in each condition, mapped reads were pooled across ChIP-seq 
replicates and regions of enrichment (peaks) were identified for the pooled ChIP-seq dataset 
relative to the pooled control using the MACS2 peak caller (version 2.0.10.20130712)35 
(https://github.com/taoliu/MACS/) using a relaxed P value of 0.01. For each histone 
modification, overlapping peaks (at least 1 bp overlap) were merged across all conditions to 
obtain a non-redundant master list of regions of enrichment. Master lists of broad domains 
of enrichment for the diffused marks H3K27me3, H3K9me3, H3K36me3 and H4K20me1 
were obtained by allowing merging peaks across conditions that were within 1kb of each 
other. Genome-wide signal coverage tracks representing per-base fold enrichment and the 
likelihood ratio of ChIP relative to control were also computed using MACS2.
Learning combinatorial chromatin states
We used ChromHMM to learn combinatorial chromatin states jointly across all four 
conditions36. ChromHMM was trained using all seven chromatin marks in virtual 
concatenation mode across all conditions. Reads from replicate datasets were pooled before 
learning states. The ChromHMM parameters used are as follows: reads were shifted in the 5′ 
to 3′ direction by 100 bp; for each ChIP-seq dataset, read counts were computed in non-
overlapping 200 bp bins across the entire genome; each bin was discretized into two levels, 
1 indicating enrichment and 0 indicating no enrichment. The binarization was performed by 
comparing ChIP-seq read counts to corresponding whole-cell extract control read counts 
within each bin and using a Poisson P value threshold of 1 × 10−4 (the default discretization 
threshold in ChromHMM). We trained several models with the number of states ranging 
from 12 states to 23 states. We decided to use a 14 state model for all further analyses since 
it captured all the key interactions between the chromatin marks and larger number of states 
did not capture significantly new interactions. To assign to assign biologically meaningful 
mnemonics to the states, we used the ChromHMM package to compute the overlap and 
neighborhood enrichments of each state relative to coordinates of known gene annotations. 
The trained model was then used to compute the posterior probability of each state for each 
genomic bin in each condition. The regions were labeled using the state with the maximum 
posterior probability. The chromatin state models and browser tracks can be downloaded 
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from http://www.broadinstitute.org/~anshul/projects/liz/segmentation/results/S14/
webpage_14.html
Differential analysis and visualization
We used the DEseq2 method that models read count statistics from replicates across 
multiple conditions to identify differentially expressed genes and regions of enrichment of 
histone marks37. Our procedures are consistent with the standards for ChIP-seq and RNA-
seq analysis determined by rigorous benchmarking as a part of the ENCODE project33. The 
minimal recommended depth for sufficient sensitivity of peak detection for histone marks 
for the human or mouse genome is ~20 million mapped reads33. However, due to limited 
amount of starting material obtained from a single mouse, we obtained ~10 million unique 
mapped reads from each biological replicate. Directly, using read counts from the original 
replicates would result in significant loss of power to detect differential events. To improve 
to improve sensitivity, for each histone mark in each condition, we pooled mapped reads 
from all replicates and created a pair of pseudo-replicates with equal number of reads 
(~30M) by randomly subsampling (without replacement) from the pool. Reads were then 
extended to the predominant fragment length. Extended-read counts were computed within 
all regions in the master peak list of a histone mark for all pseudo-replicates in all conditions 
and the table of counts was used as input to DEseq2. The raw data is available online (NCBI 
GEO GSE65159).
For RNA-seq data, the number of reads overlapping ENSEMBL gene models38 were 
determined by HT-Seq (http://www-huber.embl.de/users/anders/HTSeq/). The raw data is 
available online (NCBI GEO GSE65159). To ensure that the genes we chose were 
sufficiently quantifiable, we remove every gene where fewer than 20 reads were found 
across all samples. The resulting set of genes is found in Supplementary Table 1.
IGV39 is used to visualize the histone marks, gene expression, chromatin state, and AD 
GWAS data relative to the RefSeq gene model. Gene expression levels shown are raw read 
density. Levels of histone marks plotted are the log-likelihood ratio of ChIP signal relative 
to whole-cell extract control.
Within the DEseq2 framework of generalized linear models, we used a combination of 
different models to determine the significantly regulated genes and significantly regulated 
histone mark levels. We compared the set of all 2 week and 6 week controls to the three 
following groups: (1) the 2 week CK-p25 samples; (2) the 6 week CK-p25 samples; (3) a 
group containing both the 2 week and 6 week samples. The first two tests identified changes 
that might be 2-week or 6-week specific. The third test identified changes that might be too 
subtle to detect at any one time point alone. In each case, the most basic equation (count ~ 
CKp25 status) was used, but for a subset of samples. A stringent threshold of q < 0.01 
(Benjamini Hochberg) was used to determine significantly changing genes expression levels 
and histone mark levels. Next, to determine the temporal bias of genes expression levels and 
histone marks we built another model (count ~ time), which compared the 2 week and 6 
week CK-p25 samples. Levels considered likely to change (q<0.5) were categorizes as 
transient (2 week bias) or late-stage (6 week bias). The results of the RNA-seq analysis are 
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found in Supplementary Table 1, while the results of the histone mark analysis are in 
Supplementary Table 2.
For the histone modifications, we defined promoters using H3K4me3 peaks labeled with the 
promoter state annotation under any of the conditions (CK-p25/control and 2 weeks/6 
weeks). We define enhancers based on peaks of H3K27ac labeled by the enhancer 
chromatin state. We define Polycomb-repressed regions based on peaks H3K27me3 labeled 
by the Polycomb-repressed chromatin state. Our definitions are consistent with known roles 
of these histone modifications40. Defining the boundaries of the regulatory regions using the 
peaks of the relevant histone modifications, and not the chromatin states, maximizes our 
power to detect changes in histone mark levels.
Pathway and Gene Ontology analysis for the gene expression data were then generated 
through the use of DAVID41,42. We present the most significant biological process Gene 
Ontology category result as well as a subset of non-redundant less significant categories that 
still pass our threshold significant (q < 0.01). For the regulatory regions, GREAT (with 
default parameters) was used to find the fold enrichment in the same Gene Ontology 
categories43.
Statistical framework for comparing CK-p25 changing genes and regulatory regions to 
other data sets
A common theme throughout the analysis is the characterization of regulatory regions that 
change in the CK-p25 mouse model. The most stringent control for this characterization are 
genes or regions of the same type that do not change in CK-p25. Due to the six categories of 
direction (increasing, decreasing) and temporal pattern (transient, consistent, late-stage), we 
chose a discrete statistical framework as opposed to trying to define a ranking across these 
different conditions. To measure the overlap between these discrete categories and other 
discrete data sets, we could use either a hypergeometric P value or a binomial P value. For 
every test in the material described below, we computed both significance values and 
obtained consistent results, with only minor differences in exact P value. In general, we 
chose the hypergeometric test, which is the most direct to look at overlap of annotated 
regions. As opposed to the overlap of the CK-p25 mouse categories with other ChIP-seq 
peaks, the overlap with transcription factor binding site motifs or SNPs can be thought of as 
sampling with replacement, which lends itself to the binomial P value.
Comparison of histone marks and gene expression
As described above, DESeq2 was used determine the log fold change in expression at 2 and 
6 weeks in CK-p25 mice relative to control. Each enhancer and promoter was mapped to the 
closest ENSEMBL gene model based on distance to transcription start. For each category of 
histone mark direction and temporal pattern, we examined the enrichment of each category 
of CK-p25 gene expression change relative to unchanging genes. The significance of the 
enrichment is calculated using a hypergeometric test.
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Identification of orthologous human regions
The promoter (H3K4me3 peaks annotated as transcription start site by chromatin state), 
enhancer (H3K27ac peaks annotated as enhancer by chromatin state), and Polycomb-
repressed regions (H3K27me3 peaks annotated as Polycomb-repressed by chromatin state) 
were mapped to the human genome. BED files representing the coordinates of these peaks in 
mm9 were mapped to mm10 using liftover44. Those peaks were mapped compared to the 
human genome the UCSC multiple alignment chain files (http://hgdownload.soe.ucsc.edu/
goldenPath/mm10/multiz60way/)45. More specifically, the alignments that overlap the 
mouse peak and include hg19 were extracted. We calculated the human mouse pairwise 
alignment for each multiple alignment using the “globalms” function of biopython (http://
biopython.org/, version 1.59; python version 2.71). The highest scoring pairwise alignment 
formed base of the orthologous region in human. This region was extended on either side 
using lower scoring multiple alignments. The orthologous region in hg19 was required to be 
greater than 30 bp and no more than twice the length of the region in mouse. The mean 
conservation was examined using the PHASTCons score across placental mammals46 based 
on the same 60-way multiple sequence alignment. The mapped enhancer regions were 
annotated with their chromatin state in human hippocampus, and across all 127 cell types 
and tissues, using BEDTools47. The information from human tissues was collected 
according to protocols described in more detail in the companion publication as a part of the 
Roadmap Epigenomics project10 (http://www.roadmapepigenomics.org/). The protocols are 
approved by the NIH and no sequence information from identifiable subjects is provided.
Computational analysis of cell type proportion
To computationally estimate the relative composition of the neural and immune cell types 
we compared the changing expression patterns in our dataset to a set of established cell-type 
specific markers48–50. This analysis shows that indeed it is likely that cell type composition 
is changing in the CK-p25 mouse model, consistent with a known decrease in number of 
neurons and astrogliosis at six weeks5. In summary, a transient enrichment of monocyte 
specific transcripts was observed at 2 weeks, a consistent enrichment of microglial-specific 
transcripts was enriched at 2 weeks and 6 weeks, while astrocyte, oligodendrocyte, and 
endothelial-specific markers were primarily increased at 6 weeks (Extended Data Fig. 9a, b). 
We could also detect a signature of neuronal loss, primarily at 6 weeks as well (Extended 
Data Fig. 9a, b). Based on these results alone, it is possible that changes in cell type 
composition are contributing to some of the differences we observe in our mouse model.
We also compared our data to a published study of microglial activation in another mouse 
model of AD8, to computationally dissect out changes likely due to cell type proportion 
versus changes due to activation within cells. If the changes in our mouse model were 
primarily due to cell type proportion, then the increase we observed in the CK-p25 mice 
should be proportional to the expression level of those genes microglia. If the changes we 
observed were primarily due to activation, then the changes we observe in the CK-p25 
mouse should be proportional to the amount of activation found in during 
neurodegeneration8. Using the genes with published gene expression changes during 
activation8, we modeled these two possibilities as a linear regression problem and examined 
the relative significance of both hypotheses in the R programming language:
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CK-p25 log fold change ~ Microlglial Expression + Microglial Activation log fold change
We found that the changes in the CK-p25 mice were significantly related to the changes in 
cell activation (P = 2.9 × 10−6) as well as the changes in cell type proportion (P = 2.7 × 
10−4), suggesting that both cell activation and composition changes occur.
Comparison of gene expression in mouse model and human AD
To examine the relationship between AD in the mouse model and human, we mapped each 
1-1 orthologous gene from mouse to human in ENSEMBL (http://www.biomart.org/) 51. For 
each category of expression change in mouse, we examined how that set of genes behaved 
in human AD cases relative to controls in whole hippocampus52 as well as laser capture 
microdissected hippocampal grey matter2. To make this comparison we first downloaded 
both datasets from GEO (GSE1297, GSE28146), applied a variance stabilization 
normalization, and then used limma53 to find the log fold change in expression of all cases 
relative to controls. For each category of mouse gene expression, we calculated a P value 
based on a t-test for the bias of genes to increase or decrease in human AD relative to 
control. Because the original study52 had more confounders due to changes in grey/white 
matter proportion, we focused our analysis on the 22 cases and 9 controls from the laser 
capture samples2.
Enrichment of cofactors and transcription factors
Peaks representing both neural15,16 and immune17–19 enhancers or transcription factor 
binding were used to annotate the H3K27ac enhancers and H3K4me3 promoters. We used a 
hypergeometric test to evaluate whether or not these external annotations were enriched in 
the set of increased-level or decreased-level enhancers relative to the enhancers whose levels 
do not change. This same procedure was used to look at the enrichment of the CK-p25 
enhancer orthologs in Roadmap Epigenome data. In this case, only enhancers that map to 
human are taken to be the background.
The putative binding sites based on transcription factor binding site motifs were identified 
independent of conservation and have been previously published54. The transcription factor 
binding sites were further clustered based on similarity55. The least significant of two 
statistical test was used as a stringent measure of binding site enrichment. (1) The real 
transcription factor binding site motifs in the category of interest were compared to shuffled 
control motifs that preserved nucleotide content. (2) The real transcription factor binding site 
motifs in the category of interest were compared to the real motifs in enhancers that are 
stable in the CK-p25 mice. To estimate the significance for test (1), we use a binomial P 
value because the length distribution is different for changing regulator regions compared to 
unchanging. Then we estimate the probability of finding a site per base pair. To estimate the 
significance for test (2), we use hypergeometric test. After identifying significant 
transcription factor binding sites in categories or regulatory regions, we collapsed the results 
into clusters of almost identical motifs, representing families. The group members can be 
found in a companion manuscript10 as well as online (http://www.broadinstitute.org/
~pouyak/motifs-table/).
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Luciferase reporter assay
14 oligonucleotide gBlocks (IDT), ranging in 500–1000 nt in length, and corresponding to 
10 enhancer regions were synthesized. Each gBlock contained a constant 5′ 
GCTAGCCTCGAGGAT and 3′ ATCAAGATCTGGCCT region, for direct cloning into an 
EcoRV (NEB) linearized minimal promoter firefly luciferase vector pGL4.23[luc2/minP] 
(Promega). The resulting reporter constructs were verified by DNA sequencing. BV-2 cells 
were kindly provided by Dr. Bruce Yankner. N2a cells were purchased from the American 
Type Culture Collection and maintained following their protocols. Briefly, cells were grown 
in RPMI-1640 and DMEM respectively, supplemented with 10% fetal bovine serum (FBS) 
and 1% pen/strep, and split 1:10 every 3 days. Cells were seeded into 24-well plates 1 day 
before transfection. Transfections into BV-2 and N2a cells were performed with 1 μg of a 
pGL4.23 plasmid and 200 ng of Renilla luciferase construct pGL4.74[Rluc/TK] (Promega). 
Luciferase activities were measured 24 h post-transfection using the Dual-Glo Luciferase 
Assay (Promega) and an EnVision 2103 Multilabel Plate Reader (PerkinElmer) and 
normalized to Renilla luciferase activity. All assays were performed in triplicate.
Microglia isolation
2 week induced CK-p25 mice and age-matched controls were perfused with 50 mls PBS to 
wash away blood and minimize macrophage contamination in the brains. Hippocampal 
tissue was harvested immediately after perfusion and a single-cell suspension was prepared 
as described previously56. Fluorescence-activated cell sorting (FACS) was then used to 
purify CD11b+ CD45low microglia cells using APC conjugated CD11b mouse clone 
M1/70.15.11.5 (Miltenyi Biotec, #130-098-088) and PE conjugated CD45 antibody (BD 
Pharmingen, #553081). Cells were collected directly into RNA lysis buffer (Qiagen, 
#74104).
cDNA synthesis and qPCR
Total RNA was extracted using the RNeasy Mini kit (Qiagen, #74104) according to 
manufacturer’s instructions. RNA concentration and purity was determined using Agilent’s 
Bioanalyzer and reverse transcribed using iScript cDNA Synthesis Kit (Biorad, #170-8891). 
For gene expression analysis cDNA from three biological replicates was quantitatively 
amplified on a thermal cycler (BioRad) using SYBR green (Biorad) and gene-specific 
primers (Supplementary Table 8). The comparative Ct method57 was used to examine 
differences in gene expression. Values were normalized to expression levels of Cd11b (also 
known as Itgam). Three technical replicates were used for each gene.
eQTL Analysis
The human orthologous regions to mouse enhancers that change in the CK-p25 mouse were 
compared to control for the their enrichment to overlap regulatory SNPs from published 
eQTL studies in immune cell types under a variety of conditions25,26. Because the eQTLs 
were processed separately, we applied our own threshold (P < 1 × 10−4). We then calculated 
enrichment of human orthologs of different categories CK-p25 enhancers relative to stable 
regions and used a binomial P value to estimate the significance.
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Enrichment of AD GWAS SNPs in Roadmap enhancers
The enrichment of AD GWAS SNPs that map to Roadmap enhancer regions is calculated 
based on permutations of SNPs. Briefly, SNPs were permuted 1,000,000 times preserving 
distance to gene, minor allele frequency, and a number of SNPs in LD. The thousand 
genomes projects database was used as the reference for this information.
Comparison of regulatory regions to AD meta-analysis
The enrichment of CK-p25 human enhancer orthologs in AD was calculated by comparing 
the number changing regions that overlap SNPs4 to unchanging regions that overlap SNPs. 
We calculate the significance using a binomial P value, where the probability of success in 
the changing enhancers is based on the frequency in the unchanging enhancers. The results 
for the consistently increasing enhancers were slightly more significant when using a 
hypergeometric test instead of the binomial. To test whether the enrichment of increasing 
enhancer orthologous regions was due to the overlap with CD14+ cell enhancers, we 
repeated the above enrichment procedure within the set of CK-p25 enhancer orthologs that 
also overlap CD14+ cell enhancers. The enrichment using this control was still significant 
(3.0-fold enrichment, binomial P = 1.3 × 10−5). AD GWAS SNPs that were in a mouse 
enhancer orthologs were expanded using an LD of 0.8 and then tested for potential coding 
SNPs58 or eQTLs (Supplementary Table 7).
Extended Data
Extended Data Figure 1. Epigenomic and transcriptomic profiling of a mouse model of AD
a, Experimental design and progression pathology in the CK-p25 mice. b, Gene expression 
and histone modification levels at the SPI1 locus at 6 weeks of inducible p25 
overexpression. Profiled are histone marks associated with repression (blue); histone marks 
associated with enhancers (orange); histone marks associated with promoters (red); histone 
marks associated with gene bodies (green); RNA-seq (black).
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Extended Data Figure 2. Differential microglia-specific gene expression changes in the CK-p25 
mice
RT-qPCR of selected microglia markers and immune response genes shows upregulation of 
gene expression in FAC-sorted CD11b+ CD45Low microglia from 2 week induced CK-p25 
mice (red bars) relative to respective controls (black bars). Actb (b-actin) was used as a 
negative control. Values were normalized to Cd11b expression (n=3, *P < 0.05, two-tailed t-
test); NS, non-significant.
Extended Data Figure 3. Chromatin state conservation
a, Combinatorial patterns of seven histone modifications profiled were used to define 
promoter (1-3; A, active; D, downstream; U, upstream), gene body (4-6; tx, transcribed, 3P, 
3 prime), enhancer (7-9; G, genic, 1 = strong, 2 = weak), bivalent (10), repressed Polycomb 
(11), heterochromatin (12), and low signal (13-14) chromatin states. Darker blue indicates a 
higher enrichment of the measured histone mark (x axis) to be found in a particular state (y-
axis). b, Promoter, enhancer, and repressed chromatin states in mouse hippocampus (rows), 
as profiled in this study, align to matching chromatin states in human (columns), as profiled 
by the Roadmap Epigenomics Consortium10. Shading indicates enrichment relative to 
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human chromatin state abundance (columns). The number of regions overlapping is shown 
in each cell of the heatmap.
Extended Data Figure 4. Differential gene expression and histone mark levels at regulatory 
regions in CK-p25 mice
a–e, Shown are six distinct classes of differentially modified regions: transient (early) 
increase (pink) or decrease (light blue), consistent increase (red) or decrease (blue), and late 
(6 wk) increase (dark red) or decrease (navy blue). The heatmap shows the log fold change 
relative to 2 week controls for a, gene expression; b, H3K4me3 peaks at “TSS (transcription 
start site)” chromatin state; c, H3K27ac peaks at enhancer chromatin state; d, H3K27me3 
peaks overlapping the Polycomb repressed chromatin state; e, H3K9me3 peaks overlapping 
the heterochromatin chromatin state. Numbers denote peaks falling into each category.
Extended Data Figure 5. Relationship between changes of gene expression and regulatory 
regions in CK-p25 mice
For each class of gene expression change in the CK-p25 model (x axis), overlap with 
different histone modifications is shown (y axis) for a, H3K4me3 at promoters; b, H3K27ac 
at enhancers; c, H3K27me3 at Polycomb repressed regions. Histone modifications were 
mapped to the nearest transcription start site (Supplementary Table 3) to show the 
enrichment of the changing regulatory regions relative to those that are stable in CK-p25. 
The significance is calculated based on the hypergeometric P value of the overlap.
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Extended Data Figure 6. Enrichment of immune cell eQTLs in increasing mouse enhancers
Enrichment of eQTL SNP (y axis; −log10(binomial P < 10−4)) in monocytes and CD4+ (ref. 
25,26) is compared to the orthologous regions of CK-p25 affected enhancers relative to 
enhancers whose levels do not change.
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Extended Data Figure 7. Weak enrichment of AD GWAS SNPs at differential CK-p25 
promoters
Enrichment of AD-associated SNPs (y-axis, binomial P value) in human regions 
orthologous to different classes of mouse promoters
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Extended Data Figure 8. Enrichment of tissue-specific enhancer annotations from the Roadmap 
Epigenomics Consortium for AD-associated SNPs and mouse enhancers
Enrichment of AD-associated SNPs (y-axis, permutation P value) in tissue-specific enhancer 
annotations from the Roadmap Epigenomics Consortium (points), relative to their 
enrichment for a, increased-level and b, decreased-level (colors of different classes along y-
axis) of orthologous enhancer regions in the mouse AD model (x-axis, hypergeometric P 
value). Linear regression trend line and R2, based on Pearson correlation is shown.
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Extended Data Figure 9. Cell type composition
a, For each class of gene expression change (x-axis), shown is the enrichment of cell-type-
specific gene markers from published datasets48–50. The macrophage and monocyte 
categories are computed relative to microglia49,50. The enrichment is calculated relative to 
the genes that do not change in expression level in the CK-p25 mice. Cells in the heatmap 
are labeled based on the −log10(P value) (hypergeometric t-test). Cases where no genes 
overlapped are shown in grey. b, Summary of a, showing the inferred change in cell type 
composition across time.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Conserved gene expression changes between mouse and human AD are associated with 
immune and neuronal functions
a, Six distinct temporal classes of differentially expressed genes are denoted, transient 
(early) increase (pink) or decrease (light blue), consistent increase (red) or decrease (blue), 
and late (6 wk) increase (dark red) or decrease (navy blue). Expression is shown relative to 
the mean of three replicates at 2 week control (CK) mice. Shown are the most significant 
distinct biological process Gene Ontology categories in each class of differentially regulated 
genes (asterisk denotes enrichment of hypergeometric P < 0.01). Grey boxes indicate no 
overlapping genes. b, T-statistic identifying the bias of each differentially regulated class of 
genes in AD cases relative to controls; negative t denotes lower expression in AD, positive t 
denotes higher expression in AD. c, Enrichment of Gene Ontology categories for 
differentially expressed genes between AD cases and controls in human2. Enrichment of 
each Gene Ontology category examined in the gene expression analysis was calculated for 
d, H3K4me3 promoters (red) and e, H3K27ac enhancers (yellow). Asterisk denotes 
categories with a binomial P < 0.01. Enrichment of regulatory motifs within changing f, 
promoters (top) and g, enhancers (bottom) in the mouse AD model. Overlap of changing h, 
promoters (top) and i, enhancers (bottom) with regions shown to be bound by immune 
(orange) and neuronal (purple) transcriptional factors (TF) and co-factors profiled using 
ChIP-seq in mouse immune and neuronal tissues15–19.
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Figure 2. AD GWAS loci are preferentially enriched in increasing enhancer orthologs with 
immune function
a, Enrichment (y-axis) of changing mouse AD enhancer orthologs, with a focus on 
consistently increasing (red) category of enhancers, in 127 cell and tissue types profiled by 
the Roadmap Epigenomics Consortium10 (columns). Roadmap samples are grouped into 
fetal brain (purple), adult brain (green), immune/blood cell types (orange), and all other 
(grey). b, Cell-type-specific fold luciferase reporter expression change relative to control 
(ctrl) for selected increasing enhancer regions in BV-2 microglia (orange) vs N2A neurons 
(purple) (n=3, *P < 0.05, two-tailed t-test). c, Enrichment of AD-associated SNPs (y-axis, 
binomial P value) in human regions orthologous to the mouse enhancers. d,e, Enrichment of 
AD-associated SNPs (y-axis, permutation P value) in tissue-specific enhancer annotations 
from the Roadmap Epigenomics Consortium (points), relative to their enrichment for d, 
consistently increasing and e, consistently decreasing orthologous enhancer regions in the 
mouse AD model (x-axis, hypergeometric P value). Linear regression trend line and R2, 
based on Pearson correlation, is shown.
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Figure 3. Increasing enhancer orthologs help interpret AD-associated noncoding loci
Overlap of disease-associated SNPs (top) with increasing enhancers (2nd row, red) and 
immune enhancers in human (CD14+ primary cells) is shown for genome-wide significant 
(INPP5D and CELF1 (containing the SPI1 gene); a and b) and below-significance (ABCA1; 
c) AD GWAS loci. Roadmap chromatin state annotations for immune cells (CD14+ primary; 
E029), hippocampus (E071), and fetal brain (E81), with colors as shown in the key. Light 
red highlight denotes increasing enhancer regions tested in luciferase assay. kb, kilobases; 
Mb, megabases. d, AD associated SNP rs1377416 amplifies in vitro luciferase activity of 
putative enhancer region 38,313–37,359 base pairs (bp) upstream of SPI1 (PU.1) gene in 
BV-2 cells. n=3, P < 0.0001, one-way analysis of variance (ANOVA); **P < 0.01, Tukey’s 
multiple comparison post-hoc test. NS, nonsignificant.
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